|
Ratan
Tata joins US nanotech firm's advisory board
New York, September 17, 2008 (IANS)
Ratan
Tata, chairman of the Tata group, has joined the global advisory
board of Nanobiosym, a leading nanotechnology company in the US.
Nanobiosym, based in Medford, near Boston in Massachusetts, developed
Gene-RADAR, a portable nanotechnology platform that can rapidly
and accurately detect genetic fingerprints from any biological organism.
The
company aims to give patients worldwide real-time access to their
own diagnostic information through low-cost handheld devices that
could detect disease from a single drop of blood or saliva. Welcoming
Tata to the board, the firm's chairman and CEO Anita Goel said:
"I am inspired by his example, which provides us with a practical
roadmap for bringing cutting edge technologies into emerging global
economies and extending our reach to broad markets at the 'bottom
of the pyramid'."
Tata,
who hit international headlines with his Rs.100,000 ($2,500)Nano
car, said: "Nanotechnology has the potential to revolutionise
the way we tackle key issues facing the world today, and Nanobiosym
is working at the forefront of this revolution."
"Dr.
Goel has forged a bold model for driving technological innovation
and commercialisation, while maximising global humanitarian impact.
I look forward to working closely with her and her team," Tata,
named among the 100 most influential people in the world by Time
magazine, was quoted as saying in a company release.
Goel
is a Harvard and Massachusetts Institute of Technology (MIT)-trained
physicist and physician as well as a nanotech expert and entrepreneur.
She was named one of MIT Technology Review's top 35 science and
technology innovators in the world.
Alfred
Ford, director of the Ford Motor Company Fund and also a member
of Nanobiosym's board, said: "Behind this vision is game-changing
technology which can revolutionise healthcare globally. In the face
of growing world health crises and transnational epidemics, Dr.Goel
and Nanobiosym are redefining the rules in the battle to diagnose
disease and save lives."
|